Skip to main content
SpringerLink
Log in

Drug-Resistant Schizophrenia

Treatment Options

  • Disease Management
  • Drug-Resistant Schizophrenia
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Summary

The treatment of patients with drug-resistant schizophrenia is a major challenge for both the clinician and the patient, and requires systematic and comprehensive management.

Patients should initially be assessed to clarify that they are resistant to therapy, as opposed to noncompliant or undertreated. The dosage of existing antipsychotic should be increased. If no response is observed or intolerable adverse effects occur, an alternative typical antipsychotic should be tried. In the event of nonresponse to this alternative agent, a trial with clozapine (an atypical antipsychotic) can be initiated. In patients failing to respond to any single antipsychotic, there are some alternative somatic treatments often used in combination with antipsychotics. These include lithium, carbamazepine, benzodiazepines, β-adrenergic receptor antagonists, levodopa, reserpine and some antidepressant medications.

The reasons for nonresponsiveness are not solely drug related, with psychological and social factors also contributing. Therefore, non-drug strategies, i.e. psychological and social methods, should be used in combination with pharmacological treatments to offer the patient the most consistent benefit.

The results of all types of treatment should be evaluated regularly and carefully to allow clear conclusions concerning potential benefits to be made.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 Sept; 45: 789–95

    PubMed  CAS  Google Scholar 

  2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987

    Google Scholar 

  3. May PR, Dencker SJ, Hubbard JW, et al. A systematic approach to treatment resistance in schizophrenic disorders. In: Dencker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. BraunschweiglWiesbaden: Vieweg, 1988: 22–33

    Google Scholar 

  4. Brenner H, Dencker SJ, Goldstein M, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990; 16: 551–61

    PubMed  CAS  Google Scholar 

  5. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799–812

    Google Scholar 

  6. Kay SR, Opler LA, Fiszbein A. Significance of positive and negative syndromes in chronic schizophrenia. Br J Psychiatry 1986; 149: 439–48

    PubMed  CAS  Google Scholar 

  7. Andreasen NC, Olsen S. Negative vs positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982; 39: 789–94

    PubMed  CAS  Google Scholar 

  8. Andreasen NC. Positive vs negative schizophrenia, a critical evaluation. Schizophr Bull 1985; 11: 380–9

    PubMed  CAS  Google Scholar 

  9. Wallace CJ. Functional assessment in rehabilitation. Schizophr Bull 1986; 12: 604–30

    PubMed  CAS  Google Scholar 

  10. Davis JM, Schaffer CB, Killian GA, et al. Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980; 6: 70–87

    PubMed  CAS  Google Scholar 

  11. Marder SR, Ames O, Wirshing WC, et al. Schizophrenia. Psychiatr Clin North Am 1993; 16,3: 567–87

    Google Scholar 

  12. Tuma AH, May PRA. And if that doesn’t work, what next?. A study of treatment failures in schizophrenia. J Nerv Ment Dis 1979; 167: 566–71

    PubMed  CAS  Google Scholar 

  13. Hegarty JD, Baldessarini RJ, Tohen M, et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151 (10): 1409–16

    PubMed  CAS  Google Scholar 

  14. Kolakowska T, Williams AO, Ardern M, et al. Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiatry 1985; 146: 229–46

    PubMed  CAS  Google Scholar 

  15. Kolakowska T, Williams AO, Jambor K, et al. Schizophrenia with good and poor outcome. III: Neurological soft signs, cognitive impairment and their clinical significance. Br J Psychiatry 1985; 146: 348–57

    PubMed  CAS  Google Scholar 

  16. Collins EJ, Hogan TP, Awad MD. The pharmacoepidemiology of treatment-refractory schizophrenia. Can J Psychiatry 1992; 37: 192–5

    PubMed  CAS  Google Scholar 

  17. Keefe RSE, Mohs RC, Davidson M, et al. Kraepelinian schizophrenia: a subgroup of schizophrenia? Psychopharmacol Bull 1988; 24: 56–61

    PubMed  CAS  Google Scholar 

  18. Kinon BJ, Kane JM, Chakos M, et al. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol Bull 1993; 29 (3): 365–9

    PubMed  CAS  Google Scholar 

  19. Kinon BJ, Kane JM, Johns C, et al. Treatment of neurolepticresistant schizophrenic relapse. Psychopharmacol Bull 1993; 29 (2): 309–14

    PubMed  CAS  Google Scholar 

  20. Bareggi SR, Mauri M, Cavallaro R, et al. Factors affecting the clinical response to haloperidol therapy in schizophrenia. Clin Neuropharmacol 1990; 13 Suppl.I: 29–34

    Google Scholar 

  21. Prudo R, Munroe Blum H. Five-year outcome and prognosis in schizophrenia: a report from the London Field Research Centre of the international pilot study of schizophrenia. Br J Psychiatry 1987; 150: 345–54

    PubMed  CAS  Google Scholar 

  22. Breier A, Schreiber JL, Dyer J, et al. National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 1991; 48: 239–46

    PubMed  CAS  Google Scholar 

  23. Pickar D, Owen RR, Litman RE, et al. Clinical and biological response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49: 345–53

    PubMed  CAS  Google Scholar 

  24. Duncan E, Wolkin A, Angrist B, et al. Plasma homo vanillic acid in neuroleptic responsive and nonresponsive schizophrenics. Bioi Psychiatry 1993; 34: 523–8

    CAS  Google Scholar 

  25. Itil TM, Shapiro O, Schneider SJ, et al. Computerized EEG as a predictor of drug response in treatment resistant schizophrenics. J Nerv Ment Dis 1980; 169: 629–37

    Google Scholar 

  26. Crow TJ. Current view of the type II syndrome: significance of age of onset, intellectual impairment, and structural changes in the brain. In: Greden JF, Tandon R, editors. Negative schizophrenic symptoms: pathophysiology and clinical implications. Washington, DC: American Psychiatric Press, 1991: 161–71

    Google Scholar 

  27. Friedman L, Knutson L, Shurell M, et al. Prefrontal sulcal prominence is inversely related to response to c10zapine in schizophrenia. Bioi Psychiatry 1991; 29: 865–77

    CAS  Google Scholar 

  28. Lieberman JA, Jody O, Alvir JMJ, et al. Brain morphologic features, dopamine, eye-tracking abnormalities in first episode schizophrenia: prevalence and clinical correlates. Arch Gen Psychiatry 1993; 50: 357–68

    PubMed  CAS  Google Scholar 

  29. Pearlson GO, Marsh L. Magnetic resonance imaging in psychiatry. In: Oldham JM, Riba MB, Tasman A, editors. American Psychiatric Press review of psychiatry. Vol 12. Washington, DC: American Psychiatric Press, 1993: 347–81

    Google Scholar 

  30. Farde L, Wiese FA, Haldin C, et al. Central 02 dopamine receptors occupancy in schizophrenia patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45: 71–6

    PubMed  CAS  Google Scholar 

  31. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17: 325–51

    PubMed  CAS  Google Scholar 

  32. Boodhoo JA. Anticholinergics and antiparkinsonian drugs in psychiatry. Br J Hosp Med 1991; 46: 167–9

    PubMed  CAS  Google Scholar 

  33. Soni SD, Bamrah JS, Krska J. Effects of alcohol on serum fluphenazine levels in stable, chronic schizophrenics. Hum Psychopharmacol 1991; 6: 301–6

    CAS  Google Scholar 

  34. Miller DD, Kelly MW, Perry PJ, et al. The influence of cigarette smoking on haloperidol pharmacokinetics. Bioi Psychiatry 1990; 28: 529–31

    CAS  Google Scholar 

  35. Van Putten T, May PRA, Marder SR. Response to antipsychotic medication: the doctor’s and the consumer’s view. Am J Psychiatry 1984; 141: 16–9

    PubMed  Google Scholar 

  36. Johnson DAW. Drug treatment of schizophrenia. In: Bebbington P, McGuffin P, editors. Schizophrenia the major issues. Oxford: Heineman Professional Publishing, 1988: 158–71

    Google Scholar 

  37. Vaughn CE, Snyder KS, Jones S, et al. Family factors in schizophrenic relapse. Arch Gen Psychiatry 1984; 41: 1169–77

    PubMed  CAS  Google Scholar 

  38. Hogarty GE. Resistance of schizophrenic patients to social and vocational rehabilitation. In: Dencker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. BraunschweiglWiesbaden: Vieweg, 1988: 83–97

    Google Scholar 

  39. Berrios GE. Neuroleptic-refractory patients and their drug plasma levels. Encephale 1982; 8: 465–85

    PubMed  CAS  Google Scholar 

  40. Prien RF, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Arch Gen Psychiatry 1968; 18: 482–95

    Google Scholar 

  41. Lader M, Herrington R. Biological treatments. Oxford: Oxford University Press, 1990

    Google Scholar 

  42. Lal S, Nair NPV. Is levomepromazine a useful drug in treatment-resistant schizophrenia? Acta Psychiatr Scand 1992; 85: 243–5

    PubMed  CAS  Google Scholar 

  43. Rifkin A, Quitkin F, Carrillo C, et al. Very high dosage fluphenazine for nonchronic treatment-refractory patients. Arch Gen Psychiatry 1971; 25: 398–403

    PubMed  CAS  Google Scholar 

  44. Quitkin F, Rifkin A, Klein DF. Very high dosage vs standard dosage fluphenazine in schizophrenia. A double-blind study of nonchronic treatment-refractory patients. Arch Gen Psychiatry 1975; 32: 1276–81

    PubMed  CAS  Google Scholar 

  45. Prien RF, Kevine J, Cole JO. High dose trifluoperazine therapy in chronic schizophrenia. Am J Psychiatry 1969; 126: 305–13

    PubMed  CAS  Google Scholar 

  46. Lehmann CR, Ereshefsky L, Saklad SR, et al. Very high dose loxapine in refractory schizophrenic patients. Am J Psychiatry 1981; 138 (9): 1212–4

    PubMed  CAS  Google Scholar 

  47. Ereshefsky L, Saklad SR, Mings TE, et al. Management of chronic, refractory schizophrenic patients with high-dose loxapine. Psychopharmacol Bull 1983; 19 (4): 600–3

    Google Scholar 

  48. Baldessarini RJ, Cohen CM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79–91

    PubMed  CAS  Google Scholar 

  49. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990; 47: 754–8

    PubMed  Google Scholar 

  50. Rifkin A, Doddi S, Karajgi B, et al. Dosage of haloperidol for schizophrenia? Arch Gen Psychiatry 1991; 48: 166–70

    PubMed  CAS  Google Scholar 

  51. Volavka J, Cooper T, Czobor P, et al. Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 1992; 49: 354–61

    PubMed  CAS  Google Scholar 

  52. Curry SH, Marshall JHL, Davis JM, et al. Chlorpromazine plasma levels and effects. Arch Gen Psychiatry 1970; 22: 289–96

    PubMed  CAS  Google Scholar 

  53. Van Putten T, Marshall BD, Liberman R, et al. Systematic dosage reduction in treatment -resistant schizophrenic patients. Psychopharmacol Bull 1993; 29 (2): 315–20

    PubMed  Google Scholar 

  54. Hirsch SR, Barnes TRE. Clinical use of high-dose neuroleptics. Br J Psychiatry 1994; 164: 94–6

    PubMed  CAS  Google Scholar 

  55. Meltzer HY. Clozapine: clinical advantages and biochemical mechanisms in schizophrenia. In: Tamminga C, editor. Schizophrenia: a scientific focus. New York: Oxford University Press, 1989

    Google Scholar 

  56. Shaik S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine. Lancet 1993; 341: 116

    Google Scholar 

  57. Kerwin RW. The new atypical antipsychotics. Br J Psychiatry 1994; 164: 141–8

    PubMed  CAS  Google Scholar 

  58. Clozapine and loxapine for schizophrenia. Drug Ther Bull 1991; 29 (Pt 11): 41–2

    Google Scholar 

  59. Nyberg S, Farde L, Eriksson L. 5HT2 and D2 dopamine receptor occupancy in the living human brain. A living human study with risperidone. Psychopharmacology (Berl) 1993; 110: 265–72

    CAS  Google Scholar 

  60. Kerwin RW. Atypical antipsychotics: a history of the concept and recent research. Schizophr Monitor 1993; 3 (Pt2): 1–4

    Google Scholar 

  61. Lieberman JA. Understanding the mechanism of action of atypical antipsychotic drugs. A review of compounds in use and development. 1993: Br J Psychiatry 163 (22 Suppl.): 7S–18S

    Google Scholar 

  62. Meltzer HY, Bastani B, Kwon KY, et al. A prospective study of clozapine in treatment-resistant patients. I. Preliminary report. Psychopharmacology (Berl) 1989; Suppl. 93: 68S–72S

    Google Scholar 

  63. Paunovic VR, Marinkovic D, Timotijevic I, et al. Clozapine in the treatment of negative syndrome in schizophrenia: a threeyear follow-up study [abstract]. 17th Congress, Collegium International Neuro-Psychopharmacologicum; 1990 10-14 Sept; Kyoto, 291

    Google Scholar 

  64. Tandon R, Goldman R, DeQuardo JR, et al. Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res 1993; 27 (4): 341–7

    Google Scholar 

  65. Lindenmayer JP, Grochowski S, Mabugat L. Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. J Clin Psychopharmacol 1994; 14 (3): 201–4

    PubMed  CAS  Google Scholar 

  66. Jalenques I, Coudert AJ. Clozapine and treatment-resistant schizophrenic patients: a long term prospective study in twenty patients [in French]. Encephale 1994 XX:; 767–75

    Google Scholar 

  67. Miller DD, Perry PJ, Cadoret RJ, et al. Clozapine’s effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994; 35 (1): 8–15

    PubMed  CAS  Google Scholar 

  68. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20–6

    PubMed  CAS  Google Scholar 

  69. Jalenques I, Albuisson E. Improvement of negative-symptoms during clozapine treatment in neuroleptic-resistant schizophrenics [abstract]. Proceedings of Critical Issues in the Treatment of Schizophrenia International Academy for Biomedical and Drug Research; 1995 March 10-12; Florence, 155

    Google Scholar 

  70. Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324 (11): 746–54

    PubMed  CAS  Google Scholar 

  71. Alvir JM, Lieberman JA. A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience. J Clin Psychopharmacol 1994; 14 (2): 87–9

    PubMed  CAS  Google Scholar 

  72. Meltzer HY. Duration of a c10zapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry 1989; 46: 672

    PubMed  CAS  Google Scholar 

  73. Perry PI, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatmentrefractory schizophrenic patients. Am J Psychiatry 1991; 148: 231–5

    PubMed  CAS  Google Scholar 

  74. Schooler NR, Levine J, Sever JB, et al. Prevention of relapse in schizophrenia. Arch Gen Psychiatry 1980; 37: 16–24

    PubMed  CAS  Google Scholar 

  75. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry, II. Baltimore: Williams and Wilkins, 1989: 1591–626

    Google Scholar 

  76. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989; 50: 322–8

    PubMed  CAS  Google Scholar 

  77. Small JG, Kellams JJ, Milstein V, et al. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients. Am J Psychiatry 1975; 132: 1315–7

    PubMed  CAS  Google Scholar 

  78. Growe GA, Crayton JW, Klass DB, et al. Lithium in chronic schizophrenia. Am J Psychiatry 1979; 136: 454–5

    PubMed  CAS  Google Scholar 

  79. Carmen JS, Bigelow LB, Wyatt RJ. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry 1981; 42: 124–8

    Google Scholar 

  80. Lerner Y, Mintzer Y, Shestatsky M. Lithium combined with haloperidol in schizophrenia patients. Br J Psychiatry 1988; 153: 359–62

    PubMed  CAS  Google Scholar 

  81. Angst J, Weiss P, Weiss P, et al. Lithium prophylaxis in recurrent affective disorders. Br J Psychiatry 1970; 116: 604–14

    PubMed  CAS  Google Scholar 

  82. Schulz SC, Kahn EM, Baker RW, et al. Lithium and (carbamazepine augmentation in treatment refractory schizophrenia. In: Angrist B, Schulz SC, editors. The neuroleptic-nonresponsive patient: characterization and treatment. Washington, DC: American Psychiatric Press, 1990: 109–36

    Google Scholar 

  83. Neppe VM. Carbamazepine in non-responsive psychosis. J Clin Psychiatry 1988; 49: 22–8

    PubMed  Google Scholar 

  84. Hakola HP, Lauluma VA. Carbarnazepine in treatment of violent schizophrenic patients. Lancet 1982; 1: 1358

    PubMed  CAS  Google Scholar 

  85. Herrera JM, Sramek JJ, Costa JE. Efficacy Efficacy of adjunctive carbamazepine in the treatment of chronic schizophrenia. Drug Intell Clin Pharm 1987; 21: 355–8

    PubMed  CAS  Google Scholar 

  86. Luchins B. Carbamazepine and neuroleptics in the treatment of schizophrenia. Psychopharmacol Bull 1984; 20: 569–71

    PubMed  CAS  Google Scholar 

  87. Klein E, Beutal E, Lerer B, et al. Carbamazepine and haloperidol versus placebo and haloperidol in excited psychosis: a controlled study. Arch Gen Psychiatry 1984; 41: 165–70

    PubMed  CAS  Google Scholar 

  88. Schulz SC, Kahn EM, Baker RW, et al. Lithium and carbamazepine augmentation in treatment-refractory schizophrenia. In: Angrist B, Schulz SC, editors. The neuroleptic-nonresponsive patient: characterization and treatment. Washington, DC: American Psychiatric Press, 1990: 190–36

    Google Scholar 

  89. Okumma T, Yamashita I, Takahashi R, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenia and schizoaffective disorders. Acta Psychiatr Scand 1989; 80: 250–9

    Google Scholar 

  90. Sramek J, Herrera J, Costa J, et al. A carbamazepine trial in chronic treatment-refractory schizophrenia. Am J Psychiatry 1988; 145 (6): 748–50

    PubMed  CAS  Google Scholar 

  91. Llorca PM, Wolf MA, Lancon C, et al. Clinical efficacy of bromocriptine, carbamazepine and cyproheptadine as adjuvant to neuroleptics in twenty four chronic resistant schizophrenics [in French]. Encephale 1993; 19: 565–71

    PubMed  CAS  Google Scholar 

  92. Kidron R, Averbuch I, Klein E, et al. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Bioi Psychiatry 1985; 20: 199–228

    Google Scholar 

  93. McElroy SL, Keck PE, Pope HG, et al. Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 1989; 50: 23–9

    PubMed  Google Scholar 

  94. Wassef A, Watson DJ, Morrisson P. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: a three cases report. J Clin Psychopharmacol 1989; 9: 45–8

    PubMed  CAS  Google Scholar 

  95. Ko G, Korpi E, Freed WJ, et al. Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients. BioI Psychiatry 1985; 20: 199–228

    Google Scholar 

  96. Linnoila M, Viukar M, Hietal O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry 1976; 129: 114–9

    PubMed  CAS  Google Scholar 

  97. Nestoros IN, Suranyi-Cadotte BE, Spees RC, et al. Diazepam in high doses is effective in schizophrenia. Prog NeuroPsychol Biol Psychiatry 1982; 6: 513–6

    CAS  Google Scholar 

  98. Wolkowitz OM, Pickar D. Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148 (6): 714–26

    PubMed  CAS  Google Scholar 

  99. Lingjaerde O, Engstrand E, Ellingsen P, et al. Antipsychotic effect of diazepam when given in addition to neuroleptics in chronic psychotic patients: a double-blind clinical trial. Curr Ther Res 1979; 26: 505–14

    Google Scholar 

  100. Lingjaerde O. Effect of the benzodiazepine derivative estazolam in patients with auditory hallucinations. Acta Psychiatr Scand 1982; 65: 339–54

    PubMed  CAS  Google Scholar 

  101. Wolkowitz OM, Pickar D, Doran AR, et al. Combination alprazolam-neuroleptic treatment ofthe positive and negative symptoms of schizophrenia. AmJ Psychiatry 1986; 143: 85–7

    CAS  Google Scholar 

  102. Holden JM, Itil TM, Keskiner A, et al. Thioridazine and chlordiazepoxide, alone and combined, in the treatment of chronic schizophrenia. Compr Psychiatry 1968; 9: 633–43

    PubMed  CAS  Google Scholar 

  103. Ruskin P, Averbrukh I, Belmaker RH, et al. Benzodiazepines in chronic schizophrenia. BioI Psychiatry 1979; 14: 557–8

    CAS  Google Scholar 

  104. Ratey JJ, Sorgi P, O’Driscoll GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 1992; 53 (2): 41–6

    PubMed  CAS  Google Scholar 

  105. Lindstrom LH, Persson E. Propranolol in chronic schizophrenia: a controlled study in neuroleptic treated patients. Br J Psychiatry 1980; 137: 126–30

    PubMed  CAS  Google Scholar 

  106. Yorkston NJ, Zaki SA, Weller MP, et al. DL-propranolol and chlorpromazine following admission for schizophrenia: a controlled comparison. Acta Psychiatr Scand 1981; 63: 13–27

    PubMed  CAS  Google Scholar 

  107. Manchanda R, Hirsch SR. Does propranolol have an antipsychotic effect? A placebo-controlled study in acute schizophrenia. Br J Psychiatry 1986; 148: 701–7

    PubMed  CAS  Google Scholar 

  108. Peet M, Beethell S, Coates A, et al. Propranolol in schizophrenia: I. Comparison of propranolol, chlorpromazine, and placebo. Br J Psychiatry 1981; 139: 105–11

    PubMed  CAS  Google Scholar 

  109. Greendyke RM, Kanter DR. Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations. J Clin Psychopharmacol 1987; 7: 178–82

    PubMed  CAS  Google Scholar 

  110. Brambilla F, Scarone S, Ponzano M, et al. Catecholaminergic drugs in chronic schizophrenia. Neuropsychobiology 1979; 5: 185–200

    PubMed  CAS  Google Scholar 

  111. Gerlach J, Ludhdorf K. The effect of L-Dopa on young patients with simple schizophrenia, treated with neuroleptic drugs. Psychopharmacology (Berl) 1975; 44: 105–10

    CAS  Google Scholar 

  112. Inanaga K, Nakazawa Y, Inoue K, et al. Double-blind controlled study of L-Dopa therapy in schizophrenia. Folia Psychiatr Neurol Jpn 1975; 29: 123–43

    PubMed  CAS  Google Scholar 

  113. Kay SR, Opler LA. L-Dopa in the treatment of negative schizophrenic symptoms: a single-subject experimental study. Int J Psychiatry Med 1985; 15: 293–8

    PubMed  Google Scholar 

  114. Buchanan FH, Parton RV, Warren JW, et al. Double-blind trial of L-dopa in chronic schizophrenia. Aust NZ J Psychiatry 1975; 9: 269–71

    CAS  Google Scholar 

  115. Gattaz WF, Kollisch M. Bromocriptine in the treatment of neuroleptic-resistant schizophrenia. BioI Psychiatry 1986; 21: 519–21

    CAS  Google Scholar 

  116. Delay J, Deniker P. Methodes chimiotMrapiques en psychiatrie. Paris: Masson Ed, 1961: 496

    Google Scholar 

  117. Finn MHP, Nadolski F, Guy W, et al. Clinical, psychological, and myoneural changes in psychotic patients under oral Serpasil medication. J Nerv Ment Dis 1955; 122: 458–62

    PubMed  CAS  Google Scholar 

  118. Objective measurement of psychiatric changes produced by chlorpromazine and reserpine in chronic schizophrenia. Washington, DC: Psychiatric Research Reports of the American Psychiatric Association 1955; 1: 77–83

  119. Hollister LE, Krieger GE, Kringel A, et al. Treatment of chronic schizophrenic reactions with reserpine. Ann NY Acad Sci 1955; 61: 92–100

    PubMed  CAS  Google Scholar 

  120. Hollister LE, Traub L, Beckman WG. Psychiatric use of reserpine and chlorpromazine: results of double-blind studies. In: Kline NS, editor. Psychopharmacology. Washington, DC: American Association for the Advancement of Science, 1956

    Google Scholar 

  121. Naidoo D. The effects of reserpine (Serpasil) on the chronic disturbed schizophrenic: a comparative study of rauwolfia alkaloids and electroconvulsive therapy. J Nerv Ment Dis 1956; 123: 1–13

    PubMed  CAS  Google Scholar 

  122. Gore CP, Egan GP, Walton D. The place of reserpine in the treatment of the chronic psychotic patient. Am J Psychiatry 1957; 1J4: 333–7

    Google Scholar 

  123. Shawver JR, Gorham DR, Leskin LW, et al. Comparison of chlorpromazine and reserpine in maintenance drug therapy. Dis Nerv Syst 1959; 20: 452–7

    PubMed  CAS  Google Scholar 

  124. Berlant JL. Neuro1eptics and reserpine in refractory psychoses. J Clin Psychopharmacol 1986; 6: 180–4

    PubMed  CAS  Google Scholar 

  125. Bacher NM, Lewis HA. Long term reserpine use in selected refractory outpatients. Am J Psychiatry 1985; 142: 386–7

    PubMed  CAS  Google Scholar 

  126. Weiner N. Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Gilman AG, Goodwin LS, Rail TW, et aI., editors. The pharmacologic basis of therapeutics. 7th ed. New York: Macmillan Publishing Company, 1985: 181–214

    Google Scholar 

  127. Tuteur W, Lepson D. Combined reserpine-chlorpromazine therapy in highly disturbed psychotics. Am J Psychiatry 1955; 1J2 (3): 206

    Google Scholar 

  128. Siris SG, Morgan V, Fagerstrom R, et al. Adjunctive imipramine in the treatment of postpsychotic depression. Arch Gen Psychiatry 1987; 44: 533–9

    PubMed  CAS  Google Scholar 

  129. Siris SG, Bermanzohn PC, Mason SE, et al. Maintenance imipramine therapy for secondary depression in schizophrenia. A controlled trial. Arch Gen Psychiatry 1994 Feb; 51: 109–15

    PubMed  CAS  Google Scholar 

  130. Bennett JL, Hamilton LD. Sequential use of antidepressant drug with chlorpromazine in chronic schizophrenia. Psychiatr Q 1963; 37: 53–66

    PubMed  CAS  Google Scholar 

  131. Bucci L. The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology (BerJ) 1987; 91: 104–8

    CAS  Google Scholar 

  132. Goff DC, Brotman AW, Waites M, et al. Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990; 147: 492–4

    PubMed  CAS  Google Scholar 

  133. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on-double blind placebo-controlled study. Bioi Psychiatry 1992; 31: 698–704

    CAS  Google Scholar 

  134. Angrist B, Peselow E, Rubinstein M, et al. Partial improvement in negative schizophrenic symptoms after amphetamine. Psychopharmacology (Berl) 1982; 78 (2): 128–30

    CAS  Google Scholar 

  135. Cesarec Z, Nyam AK. Differential response to amphetamine in schizophrenia. Acta Psychiatr Scand 1985; 7I: 523–8

    Google Scholar 

  136. Van Kammen DP, Boronov JJ. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol1988 Apr; (2):; 11-21

  137. Van Kammen DP, Peters JL, van Kammen WB, et al. Clonidine treatment of schizophrenia: can we predict treatment response? Psychiatry Res 1989; 27: 297–31J

    PubMed  Google Scholar 

  138. Tamminga CA, Gotts MD, Thaker GK, et al. Dopamine agonist treatment of schizophrenia with n-propylnorapomorphine. Arch Gen Psychiatry 1986; 43: 398–402

    PubMed  CAS  Google Scholar 

  139. Tandon R, Mann NA, Eisner WE, et al. Effect of anticholinergic medication on positive and negative symptoms in medicationfree schizophrenic patients. Psychiatry Res 1990; 31: 235–41

    PubMed  CAS  Google Scholar 

  140. Correa N, Opler LA, Kay SR, et al. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J Clin Psychoparmacol 1987; 7 (2): 91–5

    CAS  Google Scholar 

  141. Brambilla F, Scarone S, Pugnetti L, et al. Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation. Psychiatry Res 1983; 8: 159–69

    PubMed  CAS  Google Scholar 

  142. Manji HK, Lander M. Bromocriptine in neuroleptic resistance. Bioi Psychiatry 1987; 22: 523–4

    CAS  Google Scholar 

  143. Levi-Minzi S, Bermanzohn PC, Siris SG. Bromocriptine for ‘negative’ schizophrenia. Compr Psychiatry 1991; 32 (3): 210–6

    PubMed  CAS  Google Scholar 

  144. Brambilla F, Gessa GL, Sciascia A, et al. Treatment of drugresistant chronic schizophrenics with an association of neuroleptics and the calcium antagonist nimodipine. Eur Psychiatry 1992; 7: 177–82

    Google Scholar 

  145. Pickar D, Wolkowitz OM, Doran AR, et al. Clinical and biochemical effects of verapamil administration to schizophrenic patients. Arch Gen Psychiatry 1987; 44: 113–8

    PubMed  CAS  Google Scholar 

  146. Gulmann NC, Bahr B, Andersen B, et al. A double-blind trial of bac10fen against placebo in the treatment of schizophrenia. Acta Psychiatr Scand 1976; 54: 287–93

    PubMed  CAS  Google Scholar 

  147. Kaminsky R, Moriarty T, Moriarty T, et al. Famotidine a histamine H2 receptor antagonist and negative symptoms of schizophrenia. Bioi Psychiatry 1991; 29: 67–8

    Google Scholar 

  148. Berger PA, Barchas JD. Pharmacology studies of bela-endorphin in psychopathology. Psychiatr Clin North Am 1983; 6: 377–91

    PubMed  CAS  Google Scholar 

  149. Meltzer HY, Busch DA, Tricou BJ, et al. Effect of (des-tyr)gamma-endorphin in schizophrenia. Psychiatry Res 1982; 6: 313–6

    PubMed  CAS  Google Scholar 

  150. Brizer DA, Hartman N, Sweeney J, et al. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. Am J Psychiatry 1985; 142: 1106–7

    PubMed  CAS  Google Scholar 

  151. Naber D, Munch U, Wissmann J, et al. Naloxone treatment for five days ineffective in schizophrenia. Acta Psychiatr Scand 1983; 67: 265–71

    PubMed  CAS  Google Scholar 

  152. Gitlin MJ, Gerner RH, Rosenblatt M. Assessment ofnaltrexone in the treatment of schizophrenia. Psychopharmacol (Berl) 1981; 74: 51–3

    CAS  Google Scholar 

  153. Inanaga K, Nakano T, Nagat T, et al. Behavioral effects of protirelin in schizophrenia. Arch Gen Psychiatry 1978; 35: 1011–4

    PubMed  CAS  Google Scholar 

  154. Brambilla F, Bonioiotti GP, Maggioni M, et al. DDAVP therapy in chronic schizophrenia: effects on negative symptoms and memory. Neuropsychobio10gy 1988; 20: 113–9

    Google Scholar 

  155. Nair NPV, Bloom DM, Nestoros IN, et al. Therapeutic efficacy of cholecystokinin in neuroleptic-resistant schizophrenic subjects. Psychopharmaco1 Bull 1983; 19: 134–6

    Google Scholar 

  156. Peselow E, Angrist B, Sudilovsky A, et al. Double blind controlled trials of cholecystokinin octapeptide in neurolepticrefractory schizophrenia. Psychopharmacol 1987; 91: 80–4

    CAS  Google Scholar 

  157. Marshall BD, Glynn SM, Midha KK, et al. Adverse effects of fenfluramine in treatment refractory schizophrenia. J Clin Psychopharmacol 1989; 9 (2): 110–5

    PubMed  Google Scholar 

  158. Ban TA, Lehmann HE, Deutsch M. Negative findings with megavitamins in schizophrenic patients: preliminary report. Commun Psychopharmacol 1977; 1: 119–22

    PubMed  CAS  Google Scholar 

  159. Salzman C. The use of ECT in the treatment of schizophrenia. Am J Psychiatry 1980; 137: 1032–41

    PubMed  CAS  Google Scholar 

  160. Fink M. Convulsive therapy: theory and practice. New York: Raven Press, 1985

    Google Scholar 

  161. Small JG. Efficacy of electroconvulsive therapy in schizophrenia, mania, and other disorders: I. Schizophrenia. Convuls Ther 1985; 1: 263–70

    PubMed  Google Scholar 

  162. Friedel RO. The combined use ofneuro1eptics and ECT in drug resistant schizophrenic patients. Psychopharmacol Bull 1986; 22 (3): 928–30

    PubMed  CAS  Google Scholar 

  163. Gujavarty K, Greenberg LB, Fink M. Electroconvulsive therapy and neuroleptic medication in therapy-resistant positivesymptom psychosis. Convuls Ther 1987; 3 (3): 185–95

    PubMed  Google Scholar 

  164. Milstein V, Small JG, Miller MJ, et al. Mechanisms of action of ECT: schizophrenia and schizoaffective disorder. Bioi Psychiatry 1990; 27: 1282–92

    CAS  Google Scholar 

  165. Klapheke MM. Combining ECT and antipsychotic agents: benefits and risks. Convuls Ther 1993; 9 (4): 241–55

    PubMed  Google Scholar 

  166. Smith K, Surphlis WRP, Gynther MD. ECT-chlorpromazine and chlorpromazine compared in the treatment of schizophrenia. J Nerv Ment Dis 1967; 144: 284–90

    Google Scholar 

  167. Taylor P, Fieminger JJ. ECT for schizophrenia. Lancet 1980; i: 1380–2

    Google Scholar 

  168. American Psychiatric Association. The practice of ECT: recommendations for treatment, training and privileging. Convuls Ther 1990; 6 (2): 85–100

    Google Scholar 

  169. Maim U. Good routine treatment in schizophrenia. In: Dencker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. BraunschweigIWiesbaden: Vieweg, 1988: 34–43

    Google Scholar 

  170. Haakenaasen J, Ugelstad E. What is effective in the psychosocial treatment of younger, chronic schizophrenic inpatients? A 10 years follow-up study. Nord Psykiatr Tidsskr 1986; 40: 255–65

    Google Scholar 

  171. Ugelstad E. Success and failure in individual psychotherapy with psychotic patients. Some follow-up considerations. Nord Psykiatr Tidsskr 1985; 39: 279–84

    Google Scholar 

  172. Goldstein MJ. Individual and family therapy of schizophrenia. In: Decker SJ, Kulhanek F, editors. Treatment resistance in schizophrenia. BraunschweigIWiesbaden: Vieweg, 1988

    Google Scholar 

  173. May PR. A step forward in research on psychotherapy of schizophrenia. Schizophr Bull 1984; 10: 564–98

    Google Scholar 

  174. Liberman RP, Van Putten T, Marshall BD, et al. Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. Am J Psychiatry 1994 lSI; (5): 756–9

    Google Scholar 

  175. Rosberg J, Stunden AA. The use of direct confrontation: the treatment-resistant schizophrenic patients. Acta Psychiatr Scand 1990; 81: 352–8

    PubMed  CAS  Google Scholar 

  176. Tarrier N, Beckett R, Harwood S, et al. A trial of two cognitivebehavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients: I. Outcome. Br J Psychiatry 1993; 162: 524–32

    PubMed  CAS  Google Scholar 

  177. Mirza S, Sunil Babu V, Vithayathil E. Treatment resistance in schizophrenia [letter]. Br J Psychiatry 1993; 162: 524–32

    Google Scholar 

  178. Chadwick P, Birchwood M. The omnipotence of voices. A cognitive approach to auditory hallucinations. Br J Psychiatry 1994; 164: 190–201

    PubMed  CAS  Google Scholar 

  179. Liberman JA. Rehabilitation psychiatrique des malades mentaux chroniques. Paris: Masson Ed, 1991

    Google Scholar 

  180. Kuehnel TG, Liberman RP, Marshall BD, et al. Optimal drug and behavior therapy for treatment-refractory institutionalized schizophrenics. In: New directions for mental health services. Geneva: World Health Organization, 1992; 53: 67–78

    Google Scholar 

  181. Kuehnel TG, Liberman RP, Marshall BD, et al. Optimal drug and behavior therapy for treatment-refractory institutionalized schizophrenics. New Dir Ment Health Serv 1992; 53: 67–78

    PubMed  Google Scholar 

  182. Garety PA, Kuipers L, Fowler O, et al. Cognitive behavioural therapy for drug-resistant psychosis. Br J Med Psychol 1994; 67: 259–71

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Centre Médico-Psychologique, CHU Saint-Jacques, 63003, Clermont-Ferrand, France

    Isabelle Jalenques

Authors
  1. Isabelle Jalenques
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jalenques, I. Drug-Resistant Schizophrenia. CNS Drugs 5, 8–23 (1996). https://doi.org/10.2165/00023210-199605010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199605010-00002

Keywords

Search

Navigation